<DOC>
	<DOCNO>NCT00866333</DOCNO>
	<brief_summary>This study evaluate efficacy safety entinostat , SNDX-275 , patient relapse refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>A Phase 2 Multi-Center Study Entinostat ( SNDX-275 ) Patient With Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>1 . Pathologic confirmation relapse refractory classical Hodgkin 's lymphoma last biopsy available . Relapsed disease define progressive disease follow systematic therapy ( y ) curative intent . Refractory disease define disease respond progress within 3 month last dose recent systemic therapy 2 . Must progress , ineligible , stem cell transplantation 3 . Documented disease radiographically measurable ( ≥ 1.5 cm large transverse dimension ) . If 1 site radiographically measurable lesion long diameter &lt; 2.5 cm , lesion must positive FDGPET biopsy . 4 . Last dose cytotoxic chemotherapy must &gt; 21 day first dose study drug . 5 . ECOG performance status 0 1 6 . Age 18 year old 7 . Total Bilirubin ≤ 1.5 x ULN AST ALT ≤ 2.5 x ULN , possible exception document HL liver involvement . 8 . Serum Creatinine ≤ 1.5 x ULN 9 . Absolute neutrophil count ≥ 1,000/µL , platelet count ≥ 50,000/µL 10 . Patients legal representative must able read , understand , sign write informed consent 1 . Patients another active cancer ( exclude basal cell carcinoma CIN/cervical carcinoma situ melanoma situ ) . Prior history cancer allow , exclude active disease within prior 5 year . 2 . Prior allogeneic stem cell transplantation require active immunosuppressive therapy within 3 month registration evidence active GVHD . 3 . Pregnant lactating woman . Women childbearing potential ( WOCBP ) must negative serum pregnancy test prior start study drug . 4 . WOCBP men whose partner WOCBP must use acceptable method contraception enrol study , period 3 month follow last dose study drug . 5 . Patients uncontrolled intercurrent illness , active uncontrolled infection , fever &gt; 38.5⁰C evaluated infection day schedule dosing . 6 . Patients treat investigational drug within 28 day prior first dose study medication , receive concurrent treatment experimental drug anticancer therapy . 7 . Prior treatment HDAC inhibitor ( e.g . valproic acid , Zolinza ( SAHA ) , romidepsin ( Istodax ) , experimental compound MethylGene 's MCGD0103 Novartis ' LBH589 ) 8 . History pericarditis pericardial effusion require medical surgical intervention last 6 month , myocardial infarction arterial thromboembolic event within 6 month , experience severe unstable angina , New York Heart Association ( NYHA ) Class III IV disease QTc interval &gt; 0.47 second 9 . Known HIV history active Hepatitis B C evidence laboratory abnormality addition positive serology . 10 . Active central nervous system lymphoma lymphoma leptomeningeal involvement 11 . Any condition ( e.g. , know suspected poor compliance , psychological instability , geographical location , etc ) , judgment investigator , may affect patient 's ability sign inform consent comply study procedures 12 . Any condition put patient undue risk discomfort result adherence study procedures 13 . History gastrointestinal disorder ( medical disorder extensive surgery ) could interfere absorption study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Relapsed Hodgkin 's Lymphoma</keyword>
	<keyword>Refractory Hodgkin 's Lymphoma</keyword>
</DOC>